301 related articles for article (PubMed ID: 37081982)
21. Modeling Tumor Immunology and Immunotherapy in Mice.
Buqué A; Galluzzi L
Trends Cancer; 2018 Sep; 4(9):599-601. PubMed ID: 30149876
[TBL] [Abstract][Full Text] [Related]
22. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
Uche IK; Kousoulas KG; Rider PJF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds.
Sivanandam V; LaRocca CJ; Chen NG; Fong Y; Warner SG
Mol Ther Oncolytics; 2019 Jun; 13():93-106. PubMed ID: 31080879
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic viruses for cancer immunotherapy.
Hemminki O; Dos Santos JM; Hemminki A
J Hematol Oncol; 2020 Jun; 13(1):84. PubMed ID: 32600470
[TBL] [Abstract][Full Text] [Related]
26. An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids.
Takahashi N; Hoshi H; Higa A; Hiyama G; Tamura H; Ogawa M; Takagi K; Goda K; Okabe N; Muto S; Suzuki H; Shimomura K; Watanabe S; Takagi M
Cells; 2019 May; 8(5):. PubMed ID: 31137590
[TBL] [Abstract][Full Text] [Related]
27. Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line.
Pyo DH; Hong HK; Lee WY; Cho YB
Cancer Biol Ther; 2020 Jun; 21(6):495-502. PubMed ID: 32208894
[TBL] [Abstract][Full Text] [Related]
28. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
29. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
[TBL] [Abstract][Full Text] [Related]
31. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
Relph K; Annels N; Smith C; Kostalas M; Pandha H
Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
[TBL] [Abstract][Full Text] [Related]
33. [Drug Development Based on Intracellular Pharmacokinetic Analysis of Molecular Target Drug in Mice Bearing Patient-derived Xenograft Model].
Hamada A
Yakugaku Zasshi; 2020; 140(5):641-648. PubMed ID: 32378664
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic strategies for gastric cancer targeting immune cells: Future directions.
Zhao Y; Bai Y; Shen M; Li Y
Front Immunol; 2022; 13():992762. PubMed ID: 36225938
[TBL] [Abstract][Full Text] [Related]
35. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
36. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
37. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
38. Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine.
Spagnol G; Sensi F; De Tommasi O; Marchetti M; Bonaldo G; Xhindoli L; Noventa M; Agostini M; Tozzi R; Saccardi C
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046719
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.
Zhao Y; Liu Z; Li L; Wu J; Zhang H; Zhang H; Lei T; Xu B
Front Microbiol; 2021; 12():707290. PubMed ID: 34367111
[TBL] [Abstract][Full Text] [Related]
40. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
